Gallium-68 radiotracers are particularly useful for diagnosing and monitoring cancer, as they can detect the presence and location of tumours in the body. Gallium-68 is produced through the decay of germanium-68, which has a half-life of 270 days. The production of gallium-68 radiotracers involves using a generator system, which consists of a column containing a resin loaded with germanium-68.
As the germanium-68 decays, it produces gallium-68, which is then eluted from the column using a solution of hydrochloric acid. Once the gallium-68 has been produced, it can be attached to a targeting molecule designed to bind to specific receptors or proteins in the body. This targeting molecule is often a peptide, antibody, or small molecule, and it can be labelled with gallium-68 using various methods, such as chelation or conjugation. One of the most common applications of gallium-68 radiotracers is imaging neuroendocrine tumours.
These tumours are difficult to detect using traditional imaging techniques, but they express specific receptors that can be targeted using radiotracers labelled with gallium-68. By administering a gallium-68 radiotracer and performing a positron emission tomography (PET) scan, doctors can detect the presence and location of these tumours with high accuracy. Gallium-68 radiotracers can also be used to monitor the effectiveness of cancer treatments.
For example, if a patient is undergoing chemotherapy or radiation therapy, a gallium-68 radiotracer can be used to monitor the response of the tumour to the treatment. If the tumour responds well, the radiotracer uptake will decrease over time, indicating that the treatment works. However, if the tumour is not responding, the radiotracer uptake will remain high, meaning alternative therapies may be necessary.
You are here:
home »
By | 9 minutes of readingYttrium-90 FAPi-46 targets fibroblast activation protein, providing effective radiotherapy for tumours and fibrotic diseases.
By | 4 minutes of readingLutetium-177 PSMA-R2 is a urea-based therapeutic agent targeting PSMA, effectively treating advanced prostate cancer patients.
The Development of Lutetium-177 PSMA-R2: A Novel Therapeutic Agent for Prostate Cancer Read Post »
By | 10 minutes of readingLutetium-177 LNC1010, a radiolabelled therapy, targets somatostatin receptors, delivering precise treatment with minimal side effects.
By | 4 minutes of readingLutetium-177 FAPI-04 revolutionises cancer treatment by precisely targeting cancer-associated fibroblasts, enabling dual imaging and radiotherapy functionalities for enhanced outcomes.
Innovative Radiotherapeutics: Lutetium-177 FAPI-04 as a Game-Changer in Cancer Treatment Read Post »
By | 9 minutes of readingLutetium-177 DPI-4452 pioneers precision radiotheranostics, revolutionising treatment for CAIX-expressing solid tumours through targeted imaging, therapy, and personalised oncology care advancements.
By | 6 minutes of readingAdvancing cancer diagnostics, the study evaluates Ga-68 FAPi-46 PET imaging’s potential to map FAP expression non-invasively in solid tumours.
By | 11 minutes of readingGallium, predicted by Mendeleev, now revolutionises medical diagnostics with its unique radiopharmaceutical applications in oncology.
By | 2 minutes of readingGallium-68 DOTATOC revolutionises neuroendocrine tumor diagnosis, enhancing PET imaging accuracy, sensitivity, and management in the medical field.
Gallium-68 DOTATOC: PET Imaging of Neuroendocrine Tumour Read Post »
By | 3 minutes of readingGallium-67 citrate is a radiopharmaceutical used for imaging infections, inflammation, cancer, and fever of unknown origin.
Gallium-67 Citrate: A Versatile Diagnostic Agent Read Post »
By | 20 minutes of readingImaging of β-amyloid plaques are necessary for clinical and neuropsychological characteristics in Alzheimer’s disease.
Gallium-68 radiotracers for Alzheimer’s plaque imaging Read Post »
